All In Biotech

Drug Trial Radar · NCT04075266

A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

An Open-Label, Parallel-Group Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

23

Actual

Start

Jan 9, 2020

Primary completion

Oct 5, 2023

Study completion Apr 26, 2032

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Aug 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 12-year study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic (PD) effects of ocrelizumab in children and adolescents ages ≥ 10 to ≤ 18 years with relapsing-remitting multiple sclerosis (RRMS). The data from this study will serve to determine the dosing regimen of ocrelizumab to be further investigated in the subsequent Phase III study in children and adolescents.

Conditions

  • Multiple Sclerosis

Interventions

  • OcrelizumabDrug

    Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks. Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Exploration Period: Area Under the Concentration Versus Time Curve of OcrelizumabTime frame: Pre-dose 5- 30 minutes and post-dose 30 mins on Days 1, 15 and 169; At any time on Days 29, 57, 85 and 113
  2. Dose Exploration Period: Maximum Concentration (Cmax) of OcrelizumabTime frame: Pre-dose 5- 30 minutes and post-dose 30 mins on Days 1, 15 and 169; At any time on Days 29, 57, 85 and 113
  3. Dose Exploration Period: Levels of CD 19+ B-cell Count in BloodTime frame: At Week 24

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Colorado Denver Childrens Hospital Rocky Mountain MS Center

    Aurora, Colorado

  • Childrens National Health Center

    Washington D.C., District of Columbia

  • Boston Childrens Hospital

    Boston, Massachusetts

  • Washington Universtiy school of Medicine

    St Louis, Missouri

  • Cleveland Clinic

    Cleveland, Ohio

  • Ospedale Pediatrico Bambino Gesù

    Rome, Lazio, Italy

  • Azienda Ospedaliera Sant'Andrea

    Rome, Lazio, Italy

  • AOU Policlinico V. Emanuele - P.O G. Rodolico

    Catania, Sicily, Italy

  • Uniwersyteckie Centrum Kliniczne

    Gda?sk, Poland

  • Uniwersytecki Szpital Kliniczny w Poznaniu

    Późna, Poland

  • Dzieci?cy Szpital Kliniczny im. Józefa Polikarpa Brudzi?skiego

    Warsaw, Poland

  • Instytut Pomnik Centrum Zdrowia Dziecka

    Warsaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.